Antibody Discovery Service
Antibody discovery is a key step that directly determines the results of antibody drug development. To obtain better antibody drugs, it is necessary to expand the range of antibodies as much as possible and accurately sort out high-quality antibodies. Our company provides high-quality antibody discovery services and has a variety of antibody discovery platforms to help you make research progress in the development of rare disease antibody therapies.
Overview of Antibody Discovery
Antibody discovery is a key step in the development of antibody drugs, which can directly affect the efficacy of antibody drugs. In the process of rare disease drug development, researchers should select reasonable antibody screening technology according to the pathogenesis of the disease and the characteristics of the target, to more efficiently screen out high-quality functional antibody candidates.
Antibody Discovery Technologies
The current antibody discovery methods include hybridoma technology, phage display technology, and single B cell antibody screening technology. Hybridoma technology is well-established and widely used for antibody preparation. Phage technology is also commonly used due to its high screening efficiency. Emerging technologies, such as single B cell screening, allow for direct screening of human monoclonal antibodies from humans, resulting in shorter development cycles compared to traditional methods.
Our company provides a wide range of antibody discovery platforms, allowing customers to choose the most suitable platform based on their specific target, downstream application, desired delivery content, and timeline. This table summarizes the main advantages and drawbacks of each antibody discovery technology.
|Single B Cell Screen-Based Antibody Discovery
|Phage Display-Based Antibody Discovery
|Hybridoma Technology-Based Antibody Discovery
|Humanized Transgenic Animal-Based Antibody Discovery
Our Antibody Discovery Service Process
Please note that this process provides a general overview and each technology may vary. You can contact our experts with specific project requirements to determine the most suitable antibody discovery technology. Alternatively, you can refer to our Therapeutic Antibody Development Platforms for more rare disease antibody therapy information.
- Alfaleh, M. A., et al. "Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol 11: 1986." (2020).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.